About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Editorial Board Spotlight
P&T’s Seattle-based neurologist, Bruce R. Ransom, is savvy, slightly sardonic, and—oh yes—smart.
Letter to the Editor
The use of the two-hour efficacy time point in evaluating triptans is debated.
Richard White, PhD, MPH
Lawrence and Sharon Prescott review some new therapies for atherosclerosis, coronary artery disease, hypertension, myocardial infarction, acute coronary syndrome, stroke, and heart failure
Lawrence M. Prescott, PhD, and Sharon L. Prescott
The authors discuss a recombinant product (Fabrazyme®) for the treatment of a rare disorder caused by an enzyme deficiency.
Julie A. Aaron, PharmD, and Nicole T. Ansani, PharmD
The author discusses recent FDA approvals for doxorubicin HCl liposome injection (Doxil®) for patients with ovarian cancer, paclitaxel protein-bound particles for injectable suspension (Abraxane™) for the treatment of breast cancer, and erlotinib (Tarceva®) therapy for patients with non–small cell lung cancer.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
The authors review therapies for essential tremor, Parkinson’s disease, dystonia, myoclonus, chorea, tic disorders, tardive dyskinesia and akasthisia, restless limbs syndrome, and Wilson’s disease.
Ali Samii, MD, and Bruce R. Ransom, MD, PhD
David Nash, MD, MBA, discusses PEACE, a P&T subcommittee set up to contain formulary costs.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains the special precautions required to avoid errors in methotrexate administration.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses the factors that might lead Congress to authorize drug importation.
Drs. Marzella and Antonopoulos review an injectable product, poly-l-lactic acid (Sculptra™), for patients with HIV-associated facial lipoatrophy.
Nino Marzella, BS, PharmD, and Marilena S. Antonopoulos, PharmD
P&T presents the latest
information about FDA approvals, drug indications, industry updates, and new devices.